ZAMP Bionews

Bionovo, Inc. (Nasdaq: BNVI) will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer [...]

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers. Concert intends to evaluate CTP-347 as a non-hormonal treatment for vasomotor symptoms (VMS or hot flashes) in patients with increased risk [...]

Concert Pharmaceuticals, Inc. announced today the presentation of data from a preclinical study demonstrating the potential of CTP-347, its novel deuterium-containing serotonin modulator, to avoid the risk of adverse drug-drug interactions when co-administered with tamoxifen, a widely-used breast cancer drug. These data were the subject of a poster presentation at the North American Menopause Society’s [...]

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that key data on sustained viral response (SVR) rates in both treatment-naïve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens will be presented at the 59th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 31 - November [...]

Genmab A/S (OMX: GEN) announced it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin’s lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have been recruited in the study. Data from these [...]